Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
The approval of this important test marks the 14th IVD to receive clearance by the CDSCO, and strengthens the company’s foundation for future growth
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
Partnership discussions focus on clinical validation, real-world evidence generation and adoption of indigenous diagnostic technologies across healthcare settings
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
Medical experts point to a growing body of research linking energy drinks to liver injury
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
The new assay consolidates screening for four major viral threats into a single workflow
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
